References
- Clark LC, Jr, Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 1966; 152: 1755–6
- Ohyanagi H, Saitoh Y. Development and clinical application of perfluorochemical artificial blood. Int J Artif Organs 1986; 9(5)363–8
- Tremper K K, Friedman A E, Levine E M. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid. Fluosol-DA, N Engl J Med 1982; 307: 277
- Waxman K, Tremper K K, Cullen B F. Perfluorocarbon Infusion in Bleeding Patients Refusing Blood Transfusions. Arch Surg 1984; 119: 721–4
- Kara K E, Ogburn PL, Jr., Julian T. Use of a Whole Blood Substitute, Fluosol-DA 20%, after Massive Postpartum Hemorrhage. Obst Gyn, 65(1)127–30
- Gould S A, Rosen A L, Sehgal L R. Fluosol-DA as a red cell substitute in acute anemia. N Engl J Med 1986; 314: 1653–56
- Spence RK. [letter], Fluosol-DA as a red cell substitute in acute anemia. N Engl J Med 1987; 315: 1677
- Riess J G. Fluorocarbon-based in vivo oxygen transport and delivery systems. Vox Sang 1991; 61(4)225–39
- Spence R K, McCoy S, Costabile J. Fluosol DA-20 in the treatment of severe anemia: randomized controlled study of 46 patients. Crit Care Med 1990; 18(11)1227–30
- Hammerschmidt D E, Vercellotti G M. Limitation of complement activation by perfluorocarbon emulsions: superiority of lecithin-emulsified preparations. Blood substitutes, TM Chang, RP Geyer. Dekker, New York 1989; 431–8
- Kent K M, Cleman M W, Cowley M J. Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol. A J Cardiol 1990; 66(3)279–84
- Hong F, Shastri K A, Logue G L. Complement activation by artificial blood substitute Fluosol: in vitro and in vivo studies. Transfusion 1991; 31: 642–647
- Riess J. G. Blood Substitutes: Where do we stand with the fluorocarbon approach to in vivo oxygen delivery, Biomaterial, Artificial Cells, Immob. Biotech 1992; 20: 183–204